Podcasts about Psoriatic arthritis

Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA Digital Patient Education in RA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis  

Description:  How do GLP-1 receptor agonists or GIP agonists work and what is the impact for my psoriatic disease? Hear dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber answer such questions and more.           Join host Archie Franklin as he takes a deep dive into the use of GLP-1 receptor agonists and GIP agonists and the convergence of systemic inflammation related to psoriatic disease with renowned dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and, cardio-immunologist Dr. Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. Learn more about the use of incretin hormones, the impact of weight management on psoriatic disease, metabolic and cardiovascular risk, as well as results from the TOGETHER-Pso and TOGETHER-PsA clinical trials.  This episode addresses the actions of incretin hormones (GLP-1 receptor agonist and GIP agonist) and how such use may be beneficial in the management of inflammation related to psoriasis and psoriatic arthritis.  Thank you to Lilly for their support of this program activity.  Timestamps: (0:00)  Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber.  (1:35)  What are incretin hormones and how GLP-1 or GIP receptor agonists (RA) inhibit appetite to initiate weight loss. (3:29)  Why GLP-1 RAs are of interest in the management of psoriasis and psoriatic arthritis. (5:23)  The metabolic, cardiovascular, and psoriatic disease convergence. (7:19)  Will reduction of inflammation impact cardiovascular risk? (10:59) Treatment challenges associated with having psoriatic disease and being overweight or obese. (13:45)  Key points around the use of GLP-1 receptor agonists when managing psoriasis and psoriatic arthritis. (17:06)  Results of the TOGETHER-PsO and TOGETHER-PsA phase 3 clinical trials combining use of an IL-17 inhibitor and a GIP and GLP-1                receptor agonist therapy. (19:07)  Having the conversation of adding a GLP-1 RA medication to a treatment regimen. (22:40)  The paradigm shift of GLP-1 receptor agonists and the impact they can have on shared inflammatory pathways. Key Takeaways: ·       Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists are two incretin hormones that assist in managing excess body weight -- which as a result can be helpful in managing inflammation in the body.   ·       Psoriasis isn't just a skin and joint disease. It's a complex network of systemic inflammation with shared inflammatory pathways that worsens with increased weight impacting the severity of the disease, and accelerates the risk of metabolic dysfunction, and cardiovascular disease.   ·       The best outcomes occur as a result of multidisciplinary collaboration to address the impact of excess weight and systemic inflammation. If you are struggling to lose weight with diet and exercise, speak with your medical team about your options including the use of GLP-1 or GIP agonists.   Guest Bios: Renowned dermatologist Ronald Prussick, M.D., Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland, specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health, first becoming interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET/CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick has since participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis and more recently the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and education oversight to the organization and its Executive leaders.  Brittany Weber, M.D., Ph.D. is a cardio-immunologist who is the Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. She is also a member of the Division of Cardiology, a clinical investigator, and imaging specialist. Dr. Weber's research integrates advanced imaging, molecular biology, clinical trials, and population health to understand how systemic inflammation and immune deregulation drives cardiovascular dysfunction. Prior to joining UT Southwestern in 2025, Dr. Weber served on the faculty at Harvard Medical School and was the Director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital, a nationally recognized clinic addressing inflammation-related heart disease through collaborative, patient centered care. Dr. Weber is also an author on the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Resources: "The Metabolic Collison and How You Can Take Control with Psoriatic Disease" podcast episode with dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan   "NPF Medical Board Issues GLP-1 Primer for Dermatologists" Press Release "Finding My Path to Managing Psoriatic Disease and Excess Weight" podcast episode featuring dermatologist Dr. Erin Boh, patient advocate Brian Lehrschal, and moderator Jennifer Bomberger. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest happenings shaping the landscape of this dynamic industry. The pharmaceutical and biotech sectors are navigating a complex landscape replete with scientific advancements and regulatory challenges. A significant legal development comes from Takeda, which faces an $885 million verdict in a landmark pay-for-delay antitrust case. This ruling highlights the intense scrutiny of pharmaceutical companies over antitrust regulations, with potential implications for drug pricing strategies and industry practices. The possibility of tripling damages under these laws could set a precedent affecting future business operations, as Takeda plans to appeal, underscoring the high stakes involved in such litigation. Meanwhile, on the regulatory front, the White House's decision to include 600 generic medications in the TrumpRx purchasing portal marks a strategic effort to improve drug affordability. While its overall impact remains uncertain, this initiative aims to bridge gaps in medication accessibility for cost-sensitive populations. Similarly, Roche's licensing agreement with the Medicines Patent Pool to allow generic versions of Xofluza in 129 developing countries is a noteworthy step towards enhancing global access to essential medicines. These efforts underscore ongoing attempts to address affordability and accessibility concerns on a global scale. In clinical developments, UCB's Bimzelx has shown promising results against AbbVie's Skyrizi in treating psoriatic arthritis, demonstrating a statistically significant reduction in disease activity compared to Skyrizi in a Phase 3b trial. With nearly half of the patients showing improved outcomes at week 16, Bimzelx is poised to become a competitive therapeutic option, potentially redefining treatment protocols for psoriatic arthritis. Novartis's termination of its contract with Chinese CDMO Porton Pharma Solutions due to regulatory issues underscores the challenges inherent in cross-border pharmaceutical partnerships. The $64 million legal claims looming over this decision highlight the financial and operational risks associated with international collaborations. Meanwhile, biopharmaceutical buyers are increasingly turning to artificial intelligence and local expertise to navigate rising licensing costs in China. Sanofi and Wave Life Sciences are making progress in addressing α1-antitrypsin deficiency (AATD), a genetic disorder that has witnessed limited therapeutic innovation for decades. Their efforts were highlighted at the American Thoracic Society meeting, showcasing ongoing attempts to bridge treatment gaps for rare diseases through next-generation approaches. Strategic investments continue to shape the industry, as evidenced by Lauxera Capital Partners' successful EUR520 million fundraising aimed at advancing healthcare technologies. Additionally, Merck's agreement to supply Keytruda for Exelixis' colorectal cancer trial exemplifies collaborative efforts crucial for advancing cancer research. These developments reflect an industry balancing innovation with regulatory compliance and market dynamics. Scientific progress is also evident in Relay Therapeutics' advancement with its PI3K inhibitor, which has shown promising Phase 2 data in treating blood vessel disorders. This underscores the potential of PI3K inhibitors to address unmet medical needs by targeting pathways significant in cancer and other diseases. The integration of artificial intelligence into drug discovery processes is another critical trend. Incyte's collaboration with Edison Scientific aims to enhance decision-making and streamline drug discovery, showcasing AI's potential to revolutionize R&D efficiency. However, persistent challenges remain as AI scales up but doesn't yet resolve clinical trial protocol issues fully. On the business front, Bristol Myers Squibb considers investing $1 billion in a Houston manufacturing plant, emphasizing strategic infrastructure investments crucial for meeting growing pharmaceutical demands. In drug approvals, AstraZeneca's Baxfendy has received FDA approval for treating uncontrolled hypertension by targeting aldosterone synthesis—offering a novel approach as a combination therapy. Moreover, Merck & Co.'s sacituzumab tirumotecan has achieved Phase 3 success in endometrial cancer trials, demonstrating superior survival outcomes compared to chemotherapy. This highlights the growing impact of targeted therapies in oncology and the ongoing shift towards precision medicine. Despite these positive developments, challenges persist. BioMarin Pharmaceutical's BMN 401 faced setbacks after missing key Phase 3 endpoints for skeletal healing in ENPP1 deficiency patients—highlighting complexities in rare disease drug development. In conclusion, these diverse developments reflect an industry steadfastly committed to advancing healthcare through scientific innovation while navigating regulatory hurdles and operational challenges. As these sectors evolve further, maintaining a balance between rapid innovation and rigorous oversight remains essential to ensuring impactful treatments reach patients worldwide promptly. Thank you for tuning in to Pharma Daily—stay informed and stay ahead of industry trends with us tomorrow!Support the show

Description: "When joint pain is present, the diagnosis of psoriatic arthritis needs to be made as soon as possible, ideally within six months to limit joint inflammation" Dr. Vinod Chandran mentions as he discusses efforts to identify a diagnostic test for those at risk of developing psoriatic arthritis.          Join host Jeff Brown as he speaks with leading rheumatologist and clinician scientist Dr. Vinod Chandran, Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto to learn more about the progress and promising results towards developing a psoriatic arthritis diagnostic test through multi-omic assays and identifying the distinct differences between psoriasis and psoriatic arthritis.  This episode provides an update on the progress to date of the NPF PsA Diagnostic Test grant initiative which has shown promising results with a potential test entering prospective study in multiple sites soon.   Thank you to Johnson and Johnson for their support of this program activity. Timestamps: (0:00)          Intro to Psoriasis Uncovered & guest welcome rheumatologist Dr. Vinod Chandran.    (0:52)          It is challenging to diagnose psoriatic arthritis with many factors leading to a delay in diagnosis. (4:56)          The start of Dr. Chandran's involvement with the PsA Diagnostic Test Grant project.   (7:55)          The different types of omics and the definition of multi-omic. (9:57)          How the multi-omic approach is used to find biomarkers relative to a specific disease pattern. (11:08)        Development of a predictive or prevention-based test using gene expression.      (13:46)        First year results identify 200 markers across different omic approaches that distinguish psoriatic arthritis from psoriasis.    (14:58)        The significance of MRNA vs mIcroRNA's use in development of a diagnostic test and how critical that is to dissemination of a                     potential test. (17:08)        Identifying the skin-joint axis in relation to different types of arthritis. (20:20)        Next steps to moving the diagnostic test research forward as a prospective study in multiple sites and the cost effectiveness of                  delivering the test.   (23:13)        If you have psoriasis, musculoskeletal, back, and joint pain think of psoriatic arthritis and be diagnosed early to maintain a good                 quality of life. Key Takeaways: ·       Given challenges associated with diagnosing psoriatic arthritis and the impact on quality of life, in 2019 NPF launched the PsA Diagnostic Test Grant project with the goal of developing an early stage test that would identify and diagnose those with psoriatic arthritis before debilitating  joint damage begins.   ·       Progress towards a PsA Diagnostic Test includes the study of multi-omic data sets where 200 distinct biomarkers have been identified leading to a greater understanding of the different pathways between psoriatic arthritis, psoriasis, and the skin joint axis.  ·       A potential diagnostic test is now moving towards the prospective study phase. Until the test is available and if joint pain is present and you have psoriasis, ask your health care provider if it could be psoriatic arthritis and treat appropriately.  Guest Bio: Vinod Chandran, MBBS, MD, DM, PhD is a rheumatologist, clinician scientist, and Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto where he is also a Professor of Medicine. His specialties include internal medicine, immunology, rheumatology, and genetic epidemiology. His research focus is on the development of biomarker-based strategies to improve early diagnosis and prognosis of psoriasis and psoriatic arthritis, identification of new treatment targets especially for those who do not respond to current therapies, and strategies to reduce the impact of disease. Dr. Chandran is a Co-Vice President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis or GRAPPA. He is an active collaborator in a multi-center research consortia such as the International Psoriasis and Arthritis Research Team and the Spondyloarthritis Research Consortium of Canada. Dr. Chandran is the recipient of research funding from the National Psoriasis Foundation for his work in identifying a "Multi-omic Diagnostic Test for PsA in Psoriasis Patients". Resources: "Understanding the NPF Psoriatic Arthritis Diagnostic Test Grant Outcomes" Advance Online. February 18, 2026.  "Managing Chronic Pain with Psoriatic Arthritis" Psoriasis Uncovered podcast episode with physiatrist Dr. Erin Maslowski, LB Herbert who lives with psoriatic disease, and moderator Susan McClelland-Tobert, a retired pediatric cardiologist who also lives with psoriatic disease. Glossary of terms: mRNA: Messenger RNA carries protein information or instructions from the DNA in a cell's nucleus to the cell's interior where the sequence is read and translated into corresponding amino acids for growing protein chains. Micro-RNA (miRNA):  Micro-RNA act as the regulator. They are short and bind to specific target mRNA's to degrade or inhibit production of protein. 

Description: "What is metabolic disease and why do I have it on top of psoriatic disease?" Hear dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan explore this collision of diseases and how you can take control to help reduce the impact of inflammation.           Join host Corinne Rutkowski as she discusses why metabolic disease occurs with psoriasis and psoriatic arthritis and what can be done to improve overall health with dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and Danielle Cahalan, a registered dietitian and coach with All Access Dietitians. Listen as they also discuss the four pillars of health, the latest evidence around use of the Mediterranean Diet with psoriatic disease, key nutrients that impact overall health from omega 3's, polyphenols, and fiber, to making small sustainable changes.  This episode offers information to help explain the connection between metabolic and psoriatic disease and what can be done to decrease health risks associated with both diseases through sustainable changes. Timestamps: (0:00)  Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and registered dietitiand and coach                  Danielle Cahalan.                                                                                              (1:27)  Definition of metabolic disease and why the risk is higher among those with psoriasis or psoriatic arthritis. (3:11)  How this bi-directional relationship impacts the management of psoriasis and psoriatic arthritis. (6:54)  The four pillars of health that can be used to reduce the risk of metabolic disease.   (11:17) Does an anti-inflammatory diet exist? (13:46) What is the Mediterranean diet and the foods that are typically included. (16:32) The impact of the Mediterranean diet on systemic inflammation, metabolic health, and severity of psoriatic disease. (21:03) The three types of healthy fats – what they are, how they work, and where to find them. (24:50) The high polyphenol Mediterranean diet from what that means to choosing nutrient dense, colorful foods. (28:04) The koebnerization of the gut microbiome and the impact of the Mediterranean diet and high fiber. (30:59) The DASH diet in combination with the Mediterranean diet lowers oxidative stress and inflammation. (33:14) Sustainability of the Mediterranean diet and flexing behavioral health changes long term.  (37:43) Start with small habit changes and then build from there to have an impact on your metabolic health.  Key Takeaways: ·       Research shows a bi-directional relationship between psoriasis and excess body weight leading to increasing severity of disease, decrease in treatment effectiveness, and the development of metabolic syndrome, a group of conditions which together raise the risk of coronary heart disease, stroke, and diabetes. ·       What you choose to eat can make an impact in managing inflammatory markers, metabolic health to increase insulin sensitivity, decrease high blood pressure, improve lipids and the gut microbiome, as well as support neuro protection and decrease cognitive decline. ·       Create small sustainable habits that make positive changes to your immune system and gradually work towards building a foundation that benefits your overall health. Guest Bios: Renowned dermatologist Ronald Prussick, M.D. is the Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland where he specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails with the latest technology and products. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health. He first became interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET?CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick also participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the NPF, which offered a review of studies addressing the impact of dietary interventions in people with psoriasis and psoriatic arthritis. Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and provides education oversight to the organization and its Executive leaders. Danielle Cahalan, MS, RDN is a licensed and registered dietitian and coach with All Access Dietitians which offers virtual nutrition support services in AZ, CA, CO, CT, FL, IL, IN, MA, MO, MT, NJ, NY, NC, OR, PA, SC, TX, VA, WA, WI, and WY. All Access Dietitians infuses the science of motivation, habit formation, and sustainable behavior change into every session that addresses weight management and metabolic health, to women's health and digestive support. Danielle's primary focus during sessions is to help her clients find that intersection between enjoyment and satisfaction with their food choices that also support their health through sustenance. It's about finding that balance between feeling empowered, energized, and confident in the ability to make decisions that impact health, wellness, and longevity. Resources: "Mediterranean Diet Pyramid: Guidelines for Healthy Eating" © 2009 Oldways Preservation and Exchange Trust www.oldwayspt.org and UCSF Weill Institute for Neurosciences Memory and Aging Center. DASH Eating Plan (Dietary Approaches to Stop Hypertension). February 25, 2026. NIH (National Heart, Lung, and Blood Institute)  Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. AMA Dermatology . Dec. 1, 2025  The Mediterranean Diet as a Potential Solution to the Gut Microbiome Dysbiosis in Psoriasis Patients Journal of Psoriasis and Psoriatic Arthritis 2024 Jan 9.

Join Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?'.

In this episode, Drs. Nilasha Ghosh and Anne Bass discuss immune-related adverse events from immune checkpoint inhibitors, focusing on psoriasis and psoriatic arthritis. They review early clinical recognition, epidemiology, and findings from a multicenter observational study evaluating apremilast, including patient characteristics, outcomes, and key limitations. The conversation also highlights insights from the HSS Checkpoint Inhibitor–Associated Arthritis Registry, the need for greater precision in rheumatology, and practical perspectives on mentorship and career development for emerging clinician–scientists.  Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis 

She shares her complex diagnostic journey across multiple autoimmune and inflammatory conditions, highlighting the uncertainty and overlap many patients experience. Cheryl and Lorraine discuss shifting from a “cure” mindset to one focused on management, the role of community (including Rheum to THRIVE), and how writing can be a powerful tool for processing and meaning-making. Together, they explore how reframing expectations, finding connection, and letting go of the illusion of control can help people feel less alone and more capable. If you're newly diagnosed, this conversation offers both validation and a gentle reminder that, over time, navigating your health and your life can become more manageable. Episode at a glance: 00:00–03:00 Introduction + Lorraine's background 03:00–08:30 Diagnostic journey across multiple conditions 08:30–12:30 Coping, loss of identity, and community support 12:30–16:00 The “acceptance paradox” and letting go of cure culture 16:00–20:00 Writing as a processing tool 20:00–28:00 The concept of “body weather” and chaotic systems 28:00–33:00 Environmental parallels and climate connections 33:00–41:00 Inside the book's metaphors and structure 41:00–50:00 Writing advice and creative process 50:00–54:00 Advice for newly diagnosed patients 54:00–58:00 Tools, quotes, and recommendations 58:00–End Thriving with chronic illness + closing thoughts Medical disclaimer:  All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Episode Sponsors Rheum to THRIVE,  an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected.  See all the details  and join the program or waitlist now! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nutritionist Leyla Muedin discusses joint inflammation—its symptoms (swelling, pain, redness, warmth, morning stiffness, reduced range of motion) and why it is usually a sign of an underlying condition rather than a disease itself. She reviews common causes including osteoarthritis (cartilage wear and tear), rheumatoid arthritis (autoimmune synovium attack with prolonged morning stiffness and fatigue), gout (uric acid crystals, often in the big toe), psoriatic arthritis, injuries, autoimmune diseases (e.g., lupus, ankylosing spondylitis, Sjogren's), infections such as septic arthritis requiring urgent care, and surrounding-tissue problems like tendonitis and bursitis. Lifestyle factors that worsen inflammation include excess weight, poor diet (including unaddressed food allergies; avoiding nightshades is suggested), insulin resistance contributing to gout, lack of exercise, smoking, and stress. Management strategies include rest, bracing, ice vs. heat, OTC anti-inflammatories, gentle low-impact exercise, anti-inflammatory foods, weight loss, treating root causes, and supplements such as glucosamine, chondroitin, MSM, bromelain, turmeric, Boswellia, and quercetin.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 19, 2027.Targeting Unmet Needs in Psoriatic Arthritis: Cases in Achieving Treatment Goals With TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

Hear leading dermatologist Dr. E. James Song and patient advocate Ana Rinck share their perspectives on the use of biosimilars to manage psoriasis and psoriatic arthritis. The use of biosimilars is growing with 24 currently on the market and more on the way for the treatment of psoriasis and psoriatic arthritis. What does this mean for you? Find out as we explore the use of biosimilars, the impact of interchangeability, what it's like switching to a biosimilar, and what questions to ask your health care provider with leading dermatologist and NPF Medical Board member Dr. E. James Song, Director of Clinical Research at Frontier Dermatology Partners, and patient advocate Ana Rinck who currently uses a biosimilar to treat her psoriasis and psoriatic arthritis.   The intent of this episode is to offer an update on the use of biosimilars and to hear the experience of those who have used biosimilars to manage psoriatic disease. This episode is sponsored by Organon. Timestamps: (0:00) Intro to Psoriasis Uncovered and guest welcome to dermatologist Dr. E. James Song, Director of Clinical Research and Co-Chief Medical Officer, Frontier Dermatology, and patient advocate Ana Rinck, who presents her experience with using a biosimilar to treat psoriasis and psoriatic arthritis.  (0:58) Definition of what is a biosimilar in comparison to a biologic which is also referred to as the original bio-originator or reference product.   (3:10) What biosimilars are available and how they are used. (4:35) The term interchangeable and what it means for use of a biosimilar. (5:46) Ana's diagnosis to treatment options starting with use of topicals to ultimately use of a biosimilar.  (7:57) Treatment discussion and choices when faced with diminishing effectiveness within a class of medications. Should a biosimilar be considered as an option?                                                                                                                                                                (9:50) Questions to consider when there's a change in treatment. (10:57) FDA announcement to simplify the development process for biosimilars and what that means for the future use of biosimilars. (13:55) What to consider when thinking of a biosimilar as a treatment option and where to find help when needed.     (14:53) The hope and equity of access that biosimilars represent is here for the appropriate individual. Key Takeaways: ·       A biosimilar is an FDA-approved biologic product that behaves and functions like a brand biologic treatment which is also called the reference product or bio-originator. There are no clinically meaningful differences between biosimilars and their reference product.  ·       The FDA has approved several biosimilars for the treatment of psoriasis and psoriatic arthritis. Some have been identified as interchangeable which means a biosimilar could be substituted for a reference product without a health care provider's approval pending state legislative rules.    ·       Don't be afraid to ask questions or access resources to assist with preparing for a medication change should that change be initiated either by yourself, your healthcare provider, or your health insurance company.    Guest Bios:   E. James Song, M.D. is a nationally recognized dermatologist and clinical researcher who is also a Clinical Instructor at the University of Washington. Dr Song is recognized as a key opinion leader in treating psoriasis and atopic dermatitis. He is actively involved in the development of new therapies for dermatologic disease and has firsthand experience with treatments before they come to market. Dr. Song has been published extensively in peer review journals and regularly participates in meetings both as a lecturer and attendee.  He is also a Medical Board member of the National Psoriasis Foundation. He believes that the best health outcomes come from shared decision making between the patient and physician. Dr. Song strives to help patients understand not only their condition, but all their treatment options.  Ana Rinck is a patient advocate and volunteer for the National Psoriasis Foundation. She developed psoriasis in 2009 following symptoms she noticed for a few years which proved to be challenging to diagnose. She managed for many years on topicals and intralesional injections. In 2018 she was diagnosed with psoriatic arthritis and started use of a biologic realizing she needed to protect her joints from further damage. She now uses a biosimilar to manage her psoriatic disease. Ana owns her own private consulting business and is an Operations and Project Manager.  Resources: -Learn more about biosimilars, interchangeability, and state substitution rules.   -Armstrong A, Callis Duffin K, Feldman S, Glick B, Kalb R, Reddy S, Schwartzman S, Yamauchi P, Calabrese C, Cordoro K, Desai S, Gladman D, Han G, Hawkes JE, Hsu S, Kircik L, Koo J, Kreuger GG, Lebwohl M, Leonardi C, Lewitt GM, Liao W, Liu C, Markenson J, Merola JF, Orbai A, Prussick R, Richardson V, Soung J, Van Voorhees AS, Wallace E, Weinberg J, Wine Lee L, Harris J, Koons S, Howard L. Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis. National Psoriasis Foundation Medical Board. 2023. -If you need help finding a dermatologist near you contact the NPF's Patient Navigation Center for assistance.   

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and strategic shifts currently shaping the landscape of these industries.To start, let's discuss a remarkable development in therapeutic treatments. UCB's Bimzelx has demonstrated superior efficacy over AbbVie's Skyrizi in treating psoriatic arthritis, as revealed by a head-to-head phase 3b clinical trial. This finding not only extends UCB's winning streak in psoriasis treatment but also positions Bimzelx as a competitive alternative in the immunology sector. The implications of this are profound, potentially influencing prescribing patterns and improving patient outcomes by offering an effective alternative for those with psoriatic conditions.In manufacturing news, Eli Lilly is making waves with its substantial $3 billion investment aimed at enhancing the global supply chain for Orforglipron, their oral GLP-1 receptor agonist. This move highlights a growing demand for GLP-1 therapies, crucial for managing type 2 diabetes and obesity. The strategic focus on oral therapies reflects a broader industry trend towards improving patient compliance compared to injectable alternatives, underscoring the importance of such innovative treatments in addressing widespread health issues. Additionally, Eli Lilly's commitment to investing $500 million into South Korea's biopharmaceutical sector signals the country's rising status as a hub for biopharmaceutical innovation and development, likely fostering collaborations and expediting novel therapeutics' development.Economically, there's compelling evidence of the impact public funding has on scientific advancement. A recent report by United for Medical Research revealed that National Institutes of Health (NIH) grants generated $94.15 billion in economic activity in 2025, supporting nearly 391,000 jobs. This underscores the dual role of public funding in advancing biomedical research and stimulating economic growth.On the regulatory front, Sandoz is making a strategic move to establish a standalone unit dedicated to biosimilars. As we enter what Sandoz describes as a 'golden decade' of patent expirations, this realignment reflects anticipation of expansion opportunities within the biosimilars market. Such preparations suggest increased competition and potentially more affordable biologic therapy options as major drugs lose patent protection.Technological advancements are further shaping industry operations. BD's partnership with Sinteco to automate pharmacy logistics in Europe is part of a broader push to integrate robotics into healthcare processes. This aligns with digital transformation trends across the sector aimed at improving efficiency and reducing human error. Meanwhile, Medtronic's former diabetes division Minimed has achieved European approval for its 780G insulin pump system, which integrates with Abbott's continuous glucose monitor (CGM). This approval is noteworthy for enhancing diabetes management through automation of insulin delivery based on real-time glucose monitoring, representing a significant step forward in closed-loop systems.A notable technological initiative comes from ARPA-H with their program focused on developing wearable biosensors under the Delphi initiative. These sensors aim to enhance personal health monitoring capabilities across various devices, aligning with trends towards personalized medicine and digital health technologies.Despite these positive strides, challenges persist. The closure of F5 Therapeutics highlights early-stage biotech struggles amid competitive pressures. Regulatory setbacks also continue to pose challenges; Novo Nordisk recently received an FDA warning letter following inspection issues at its U.S. headquarters.Collectively, these trends reflect an industry resiliently pursuSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.We start with a significant personnel change at the FDA, where Vinay Prasad, M.D., is set to depart by the end of April. Known for his contentious interactions with the biopharma industry, particularly concerning vaccines and cell and gene therapies, his departure may signal shifts in regulatory priorities and approaches. Industry stakeholders are closely watching how his exit will affect upcoming decisions and relations between regulatory bodies and biopharma companies.In a strategic collaboration, Novo Nordisk and Hims & Hers have settled their public disputes by agreeing to distribute Novo's Ozempic and Wegovy through Hims' telehealth platform. This partnership highlights the increasing importance of digital health platforms in expanding medication access, particularly for chronic conditions like obesity and diabetes. This trend reflects a broader movement where legacy pharmaceutical companies are turning to digital avenues to enhance patient reach.On the clinical trial front, Ipsen has decided to halt the development of its lymphoma drug Tazverik after safety concerns were raised by an independent data monitoring committee. This decision underscores the rigorous safety standards in place for clinical trials and the ongoing challenge of balancing potential therapeutic benefits against safety risks. Similarly, Roche's oral SERD giredestrant failed to meet its primary endpoint in a phase 3 trial for first-line breast cancer treatment, raising questions about the limits of selective estrogen receptor degraders despite previous successes in adjuvant and second-line settings. The complexity of translating promising mechanisms into consistent clinical outcomes across different stages of treatment is highlighted here.Regulatory challenges remain a significant theme, with Novo Nordisk's Indiana plant facing scrutiny that led to the FDA rejecting Incyte's application for Zynyz as a first-line treatment for non-small cell lung cancer. This incident underscores how manufacturing issues can heavily impact drug approval processes and highlights the critical nature of compliance with regulatory standards.In terms of new drug approvals, Bristol Myers Squibb has received FDA approval for Sotyktu, a first-in-class oral TYK2 inhibitor for treating psoriatic arthritis. This approval not only broadens treatment options for patients but also reinforces the ongoing trend towards developing targeted therapies with novel mechanisms of action. Additionally, Bristol Myers Squibb is gaining momentum with its cereblon E3 ligase modulator (celmod), mezigdomide, achieving statistically significant improvement in progression-free survival among multiple myeloma patients in a Phase 3 trial. This success solidifies BMS's position in hematologic oncology and demonstrates the potential of targeted protein degradation as a therapeutic strategy.The industry is also witnessing significant financial transactions and restructuring efforts. Lonza's decision to sell a majority stake in its capsule business to Lone Star Funds for $3 billion reflects strategic realignments as companies focus on core competencies while leveraging partnerships to optimize business operations.Meanwhile, regulatory scrutiny persists as Democratic lawmakers are investigating 11 pharmaceutical companies regarding their pricing agreements under the previous administration's "most favored nation" clause. This inquiry aims to understand whether these deals have indeed resulted in cost savings for Medicaid, highlighting ongoing concerns about drug pricing transparency and affordability.In another strategic move aimed at bolstering innovation, Regeneron reported promising results from a phase 3 trial conducted by its Chinese partner on a drug mirroring Zepbound's efficacy in obesity treatmenSupport the show

Psoriatic arthritis management is evolving fast, but bridging the gap between clinical evidence and patient experience remains the ultimate challenge. When multidisciplinary teams and patients truly sync, care transforms. i3 Health recently convened a Multidisciplinary Task Force to discuss early screening, comorbidities, and therapeutic optimization. In this exclusive follow-up interview, we sit down with Archie Franklin, MBA—a veteran PsA patient and Task Force moderator—to go beyond the data. Listen now to hear a unique, dual-perspective look at the changing treatment landscape, sharing candid reflections on how clinicians can bridge communication gaps and practically elevate outcomes for every patient. Click the link to view the Task Force and claim your free CME/NCPD/CPE credit: https://bit.ly/4h5NSKb

Send us a textIn this episode, we discuss an approach to psoriatic arthritis. Written by: Dr. Inara Mawji. Reviewed by Dr. Tanveer Towheed (Rheumatology) and Dr. Don Thiwanka Wijeratne (General Internal Medicine).Support the show

"Help! It's winter and my psoriasis and psoriatic arthritis is flaring." Listen as certified physician assistant Eileen Cheever offers tips to help manage psoriasis and psoriatic arthritis flares that occur during the winter months.          Join host Corinne Rutkowski as she explores tips for managing psoriasis and psoriatic arthritis when cold weather flares the disease with Certified Physician Assistant Eileen Cheever from Clearview Dermatology. Listen as they discuss why flares occur and tips for improving flares from humidity, moisturizing products even for palmoplantar psoriasis, types of fabrics to layer, addressing aches and pains with psoriatic arthritis, use of rescue therapy, to stress and mood changes.  This episode offers information to help address winter flares that may cause you to struggle with your psoriatic disease during cold weather. Timestamps: (0:00) Intro to Psoriasis Uncovered & guest welcome Certified Physician Assistant Eileen Cheever. (1:15) Definition of a psoriasis or psoriatic arthritis flare. (2:32) How cold weather could be connected to winter flares of psoriatic disease. (4:11) Tips for addressing dryness and lack of humidity in the home.  (6:13) Products that help moisturize your skin and when is the best time to apply it to your skin. (8:56) Products for moisturizing the hands and feet with palmoplantar psoriasis.  (12:33) Types of fabrics to layer in the winter to help decrease the itch while staying warm. (14:15) Tips for addressing the aches and pains that come with cold winter months. (16:22) Medication changes vs use of rescue therapy for treating a winter flare. (17:51) Tips to help manage overall health, stress, and mood. (21:37) Reach out to your health care provider if you are struggling with your psoriatic disease. Key Takeaways: ·       While we don't completely understand the connection, 4 out of 10 people identify winter as the season that flares their psoriasis. ·       Factors that contribute to cold weather flares include lack of moisture or humidity in the air, viruses or flu, long heated showers that lead to dry, itchy skin, itchy fabrics, stress, and depression with dark days. ·       Strategies to address winter flares include various moisturizing products, maintaining 60% humidity, choosing breathable fabrics, lifestyle choices, and keeping your dermatologist and rheumatologist informed should rescue therapy be needed. Guest Bio: Eileen Cheever is a certified dermatology physician assistant (PA-C) with a clinical practice at Clearview Dermatology where she treats adults and children with a variety of diseases of the skin, hair, and scalp including psoriasis. She is a diplomate member of the Society of Dermatology Physician Assistants, a founding advisory board member for Elevate Medical Education, a member of the American Academy of Physician Assistants, and a member of the NPF Advanced Practice Provider (APP) Advisory Committee. She has a passion for providing education and lectures frequently at dermatology conferences across the country. Resources: Seasonal Flares Guide. National Psoriasis Foundation 2023©. 8 Must-Have Lotions. Advance Weekly. Updated September 30, 2025.    "Managing Chronic Pain with Psoriatic Arthritis"  podcast episode addressing why pain occurs, its  impact, and what can be done to manage pain both physically and emotionally.

This week's bonus episode completes our two-parter on psoriasis, as we hear from PBHP member, Kate Dunbar, who prior to the adoption of a whole food plant-based diet was significantly affected by the disease. She has gone on to run marathons, and is the creative master behind many of PBHP's factsheets.Her story is an inspiration to anyone suffering from an autoimmune disease who may have been told diet and lifestyle don't matter. Her experience has even been written up as a case study. https://pubmed.ncbi.nlm.nih.gov/34366737/Kate is always very generous with sharing her time and passion regarding the healing powers of food. You can follow her on Instagram @kate.dunbar, find her on Facebook, or email her,  kate-dunbar@hotmail.com 

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Psoriatic Arthritis⁠⁠ ⁠from the MSK section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Arthritis affects millions of people worldwide, but are you aware of the hidden symptoms and surprising causes that could be lurking? In this episode, Dr. Gundry dives deep into the three most common types of arthritis—Rheumatoid Arthritis, Psoriatic Arthritis, and Osteoarthritis—and reveals why joint pain isn't always the first sign. Discover how conditions like numbness, tingling, and even voice changes could indicate something more serious, like rheumatoid arthritis.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Catch up on some of the most interesting and impactful developments of 2025, from research and new treatments for chronic hand eczema, emerging oral therapies for psoriasis and AD, and even advances in cosmetic dermatology. DEF Faculty and Advisory Council members weigh in on some of the key developments with an emphasis on clinical implications. And they look ahead to 2026. Plus, updates on trichoscopy and AI.Featuring: Brad Glick, Darren West, Hillary Baldwin, Roman Bronfenbrener, Kara Gooding, Sandri Johnson, Linda Stein Gold, Joe Gorelick, Lisa Swanson, Ted Rosen, Gilly Munavalli, Matt Bruno, David CotterLike what you're hearing? Want to learn more about the Dermatology Education Foundation? Explore assets and resources on our website.

Drs. Jack Cush and Artie Kavanaugh preview the upcoming RNL 2026 meeting in Dallas, TX on February 7 & 8, 2026. Register at RheumNow.Live Below is the program: Saturday, February 7, 2026, 7:50 - 8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD I - Rheumatoid Arthritis: Achieving Better Outcomes 8:00 – 8:30 am Mortality in RA: A Story of Decline, Delay, or Plateau? Elena Myasoedova, MD 8:30 – 9:00 am The Mucosal Hypothesis of Rheumatoid Arthritis Kristen Demoruelle, MD 9:00 – 9:30 am ILD in RA – Recent Advances Jeffrey Sparks, MD 9:30 – 10:00 am Rheumatoid arthritis Faculty Q&A 10:00 - 10:15 am STEP 1: Placebos in Rheumatology Andreas Kerschbaumer, MD 10:15 -10:30 am STEP 2: Disease Modification in Osteoarthritis Tuhina Neogi, MD PhD 10:30 – 11:05 Break 11:05 - 12:10 pm POD II – Advancing Practice 11:05 – 11:30 am Obesity & Inflammation: Weight Management in Rheumatology Uzma Haque, MD 11:30 - 11:55 am Mitigating risk in Rheum Pts undergoing surgery Susan Goodman, MD 11:55 -12:10 pm Practice Panel Faculty Q&A 12:10 – 1:00pm Lunch 1:00 – 3:00 pm POD III – Decisions in Psoriatic Arthritis 1:00 - 1:30 pm Paradoxical Psoriasis and Strange Reactions Joseph Merola, MD 1:30 - 2:00 pm Why Do Plain X rays in Psoriatic Arthritis Arthur Kavanaugh, MD 2:00 - 2:30 pm IL-23 vs IL-17 inhibitors in PsA Andre Ribero, MD 2:30 - 3:00 pm Past, Present & Future of Gout Robert Terkeltaub, MD 3:00 - 3:30 pm Psoriatic Faculty Q&A 3:30 - 4:05 pm Break 4:05 - 4:20 pm STEP 3: Helicobacter Pylori update Byron Cryer, MD 4:20 - 4:35 pm STEP 4: History of Gout Robert Terkeltaub, MD 4:35 – 5:15 pm Keynote Address: 50 Years of Osteoporosis Michael McClung, MD 5:30 – 7:00 pm Reception Sunday, February 8, 2026 Day TOPIC Speaker 7:50-8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD IV – Staying Ahead of Spondyloarthritis 8:00 – 8:30 am Diagnosing Axial Spondyloarthritis in 2026 Denis Poddubnyy, MD 8:30 – 9:00 am Spondyloarthritis Complications Jessica Walsh, MD 9:00 – 9:30 am 2026 Advances in Spondyloarthritis Catherine Bakewell, MD 9:30 – 10:00 am Spondyloarthritis Faculty Q&A 10:00 – 10:15 am STEP 5: Asymptomatic Elevation of CK Rojit Agarwal, MD MS 10:15 – 10:30 am STEP 6: Update on Myositis Antibodies Rojit Agarwal, MD MS 10:30 – 11:05 am Break 11:05 – 12:10 am POD V – Highlights in Autoimmune Disease 11:05 - 11:35 am SMILE Study – Hydroxychloroquine in ANA+ Arthralgia Nancy Olsen, MD 11:35 – 12:05 am Sjogren's Treatment Landscape in 2026 Matthew Baker, MD 12:05 - 12:20 pm Autoimmune Faculty Q&A 12:20 – 1:25 pm POD VI - Large & Small Vessel Vasculitis 12:20 – 12:45 pm Embracing Relapses in PMR and GCA Michael Putman, MD 12:45 - 1:10 pm Small vessel vasculitis Clay Cockerell, MD 1:10 - 1:25 pm Vasculitis Faculty Q&A 1:30 pm Adjourn

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

Description: Chronic pain can be difficult to live with. If you have psoriatic arthritis you know all too well what that means. Listen as physiatrist Dr. Erin Maslowski and LB Herbert offer ways to manage pain before it manages your life.  Join host Susan McClelland-Tobert, a retired pediatric cardiologist who also lives with psoriatic disease as she uncovers the topic of what is chronic pain and how to manage it with Dr. Erin Maslowski, a physiatrist at Emplify Health System who specializes in physical medicine, rehabilitation and pain management, along with LB Herbert who also lives with psoriasis and psoriatic arthritis, and knows all too well what it means to live with pain, developing her own pain tool kit. Hear different strategies for managing initial flares to when pain escalates. Pain doesn't have to dictate how you live your life.  This episode addresses why pain occurs, it's impact, and what can be done to manage pain both physically and emotionally. Timestamps: (0:23)  Intro to Psoriasis Uncovered & guests physiatrist Dr. Erin Maslowski and LB Herbert (1:48)  The unpredictability of pain and what pain means to LB. (2:31)  The science behind what happens in the body when acute and chronic pain occurs. (5:08)  General principles and first steps to managing pain associated with inflammatory arthritis. (11:00) Recognition of flares and taking action to reduce the impact before pain escalates.        . (14:02) Steps to address the chronic pain cycle as it escalates such as steroid injections and                     medications that change how the brain perceives pain signals. (20:54) Side effects and cautions for use of pain management medications. (24:17) What and who LB turns to for managing her pain. (25:50) Support resources and who to consider as part of a pain management team.   (33:16) Overcoming the stigma of mental health and "it's all in your head". (34:45) Addressing the challenge of fatigue that often comes with pain. It's more than feeling                 tired.  (39:32) Activities to keep the body moving to help avoid stiff joints.          . (42:11) What's on the horizon for managing pain. (44:55) Start small, experiment with change, but above all give yourself grace if you're not able to           do something. Gain what control you can to live your life your way. Key Takeaways: ·       Chronic pain (existing for more than 3 months) occurs when ongoing inflammation keeps signaling pain via the nervous system becoming hypersensitized and greater than the original pain signal. This can occur even when inflammation is managed and in control.   ·       Treating chronic pain is complicated however there are many different avenues to help minimize pain associated with inflammatory diseases such as psoriatic arthritis.   ·       Management of chronic pain involves a variety of specialists and support to help address the         physical and emotional impact of living with chronic pain. Guest Bios: Dr. Erin Maslowski is a board-certified physician, physiatrist, at Emplify Health System where she specializes in Physical Medicine, Rehabilitation, and Orthopedic Sports Medicine providing care for musculoskeletal and spine injuries and pain management including image-guided injection procedures. She has expertise in treating arthritis, spinal stenosis and spondylosis, rotator cuff injury, and other conditions with the ultimate goal of restoring function after injury to the muscle, bone, soft tissue, or nervous system.  Dr. Maslowski is a Clinical Assistant Professor at the University of Wisconsin School of Medicine and Public Health where she teaches both medical students and residents. She has over 15 years of clinical experience in physical medicine and rehabilitation.   LB Herbert, has been living with the challenge of managing pain associated with psoriatic arthritis for 16 years, even developing her own tool kit through the years. She has shared what's she's learned on other episodes of this podcast, through articles, and as a One-to-One Program mentor for the National Psoriasis Foundation. LB began her journey in 2009 with back pain. Following many years of being misdiagnosed she finally found a rheumatologist who put all her symptoms together to diagnose her with psoriatic arthritis and place her on an appropriate treatment path. She states "my biggest challenge is not knowing what each day will bring, what the symptoms will be, and if I wake up and flare. It's a continuous unknown." Resources: Chronic Pain kit  NSAIDS for Psoriatic Disease  Podcast episode: "Living with Chronic with Chronic Pain and Fatigue in PsA and SpA" with rheumatologist Dr. Philip Mease, Dr. Ernest Choy, from Cardiff University School of Medicine, with patients Melissa Leeolou and Minionette "Mini" Wilson who discuss causes, symptoms, risks, and tips for managing chronic pain and fatigue successfully.   

Replay of RheumNow Live 2025 - Psoriatic Arthritis Sponsored by AbbVie Featuring:  Dr. Alexis Ogdie - Can Aggressive Treatment of Psoriasis Prevent PsA? Dr. Artie Kavanaugh - Combination Biologic Therapies in PsA Dr. Kenneth Gordon - Head-to-head Studies in Psoriatic Disease – What have we learned?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CKQ865. CME/AAPA/IPCE credit will be available until October 23, 2026.Tackling Obesity in Psoriatic Arthritis: Key to Better Outcomes and Overall Health In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CKQ865. CME/AAPA/IPCE credit will be available until October 23, 2026.Tackling Obesity in Psoriatic Arthritis: Key to Better Outcomes and Overall Health In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CKQ865. CME/AAPA/IPCE credit will be available until October 23, 2026.Tackling Obesity in Psoriatic Arthritis: Key to Better Outcomes and Overall Health In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CKQ865. CME/AAPA/IPCE credit will be available until October 23, 2026.Tackling Obesity in Psoriatic Arthritis: Key to Better Outcomes and Overall Health In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

DERM on RheumNow PODCAST (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES 1. Skin Biopsies to Predict Scleroderma Outcomes?  2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8 3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis  https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis    4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH   5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz 6. Mediterranean Diet Efficacy in Psoriasis   7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Episode Description:  Listen as Kim Beer, Senior Vice President of Policy and External Affairs with the National Health Council, and Dermatologist, Dr. Jeffrey Cohen discuss the 2025 Medicare changes in relation to psoriatic disease and what's to come in 2026 with Jason Harris, Vice President of Government Relations and Advocacy at NPF.  Join this discussion about what changes occurred with Medicare in 2025 that impact psoriatic disease care, outcomes to date, what's to come in 2026, and what you should consider when choosing health care plans during open enrollment with Kim Beer, Senior Vice President of Policy and External Affairs with the National Health Council, Dermatologist, Dr. Jeffrey Cohen, Director of the Psoriasis Treatment Program at Yale University School of Medicine, and Jason Harris, Vice President of Government Relations and Advocacy at NPF.  The intent of this episode is to increase knowledge of the 2025 Medicare changes, what's to come, and how such changes impact psoriatic disease from coverage of prescriptions to overall health care. This episode is sponsored by Novartis. Timestamps:   (0:24) Intro to Psoriasis Uncovered and guest welcome Kim Beer, Senior Vice President of Policy   and External Affairs with the National Health Council, and Dermatologist, Dr. Jeffrey Cohen, Director of the Psoriasis Treatment Program at Yale School of Medicine. (2:25) Perspectives on current health care coverage in Medicare.    (5:14) Biggest changes to Medicare in 2025. (6:36) What is the Medicare Prescription Payment Plan and price negotiation for specific medications. (8:22) Challenges associated with the 2025 Medicare changes from a physician's perspective. (13:10) Price negotiation process via CMS  (Centers for Medicare and Medicaid Services) with the first 10 drugs price effective in 2026.   (17:52) Plan ahead and what to anticipate when choosing the right Medicare plan. (20:04) What the National Health Council and other patient advocacy organizations are doing to assess the impact of the CMS changes and identify steps for moving forward. (21:49) Medicare changes for 2026 that affect deductibles for health care services, prescription drug coverage, and vaccinations. (28:38) Potential assistance options for people who have Medicare insurance. (31:32) The role of patients in providing feedback on policy changes. (33:45) Changing from a commercial insurance plan to a Medicare Plan and what to think about when viewing plan options during the open enrollment period. (37:07) Be part of the process – let your voice be heard by sharing your experiences to help effect change. 3 Key Takeaways: ·       There are four key parts to Medicare health insurance (Part A, B, C and D) which underwent changes in 2025 including a payment cap for prescriptions and availability of a 12 month Prescription Payment Plan to opt in for medications. Additional changes are coming in 2026 including enactment of a price negotiated list of 10 medications. ·       The impact of such changes are both positive (better predictability and affordability) yet also reactionary. Such changes and potential impact should be considered when identifying plan coverage for health care and prescriptions during the open enrollment Medicare period of October 15 to December 7th.   ·       Be involved by telling your story about the impact of Medicare changes and find a trusted health care provider who is willing to work with you to identify an effective treatment plan that aligns with your health care needs and coverage. Guest Bios:   Dermatologist Jeffrey Cohen, M.D., MPH, is the Director of the Psoriasis Treatment Program and the Director of Safety with the Department of Dermatology at Yale University School of Medicine where he is also an Associate Professor of Dermatology and Biomedical Informatics and Data Science. Dr. Cohen treats a variety of skin conditions with a special interest in diseases of the immune system such as psoriasis and eczema tailoring treatments for each individual. He is the author of over 150 peer-reviewed articles on psoriasis and other topics in dermatology. Dr. Cohen serves on the Editorial Board of the Journal of the American Academy of Dermatology, is a Senior Editor for NPF's professional journal for health care providers Journal of Psoriasis and Psoriatic Arthritis, is a Councilor of the International Psoriasis Council, and serves on the Medical Board of the National Psoriasis Foundation.  Kimberly (Kim) Beer is Senior Vice President of Policy and External Affairs at the National Health Council (NHC) of which the National Psoriasis Foundation is a member. Kim leads strategic policy initiative and advocacy efforts to improve the lives of individuals with chronic conditions and disabilities. As a member of the NHC's executive leadership team, she helps to ensure access to high-quality, affordable healthcare for all Americans which includes advocating for policy and health care benefits within Medicare. Resources: For more reources and information about Medicare Contact the Patient Navigation Center to learn more about Medicare, find a health care provider, learn about treatments, or programs that may lower costs.   

To have your question featured in a future video, please use this link: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/

No one knows your body as well as you do, so it's vital that you be involved in your own care. Hear a rheumatologist discuss how to self-advocate and why it's important. *Visit the Live Yes! With Arthritis Podcast episode page to get show notes, additional resources and read the full transcript: https://arthr.org/liveyes-ep139 (https://arthr.org/liveyes-ep139) * We want to hear from you. Tell us what you think about the Live Yes! With Arthritis Podcast. Get started by emailing podcast@arthritis.org (podcast@arthritis.org). Special Guest: Dr. Julius Birnbaum.

In this episode of the Live Yes! With Arthritis podcast, we'll explore insights and tips to properly prepare you for joint surgery — from pre-hab to coming home and beyond. *Visit the Live Yes! With Arthritis Podcast episode page to get show notes, additional resources and read the full transcript: https://arthr.org/liveyes-ep138 (https://arthr.org/liveyes-ep138) * We want to hear from you. Tell us what you think about the Live Yes! With Arthritis Podcast. Get started by emailing podcast@arthritis.org (podcast@arthritis.org). Special Guest: Alan H. Beyer, MD, FACS .

Arthritis Advocates discuss how they help change laws and policies to break down barriers to health care so all people can live better with arthritis — and how you can, too. *Visit the Live Yes! With Arthritis Podcast episode page to get show notes, additional resources and read the full transcript: https://arthr.org/liveyes-ep137 (https://arthr.org/liveyes-ep137) * We want to hear from you. Tell us what you think about the Live Yes! With Arthritis Podcast. Get started by emailing podcast@arthritis.org (podcast@arthritis.org). Special Guests: Anna Hyde and Deb Constien.

GLP-1 medications like Ozempic were designed to treat diabetes—but they're quickly becoming known for weight loss and possible kidney benefits. Kidney doctor Holly Kramer and kidney patients Patrick Gee, and Jane DeMeis, are here to break down what these medications are, how they work, and what people with kidney disease need to know.   In today's episode we heard from: Holly Kramer, M.D., MPH, is a practicing nephrologist who conducts research connecting nutrition and kidney health. Her connection to the National Kidney Foundation was inspired by her mom, who was a dialysis nurse and helped create some of the first dialysis units in Northwest Indiana. Dr. Kramer finds being on the NKF Board important, because it is the largest, patient-centered organization focusing on kidney disease. Her long-term goal is to increase national funding for kidney disease research and to heighten awareness about chronic kidney disease. Jane DeMeis  became involved with the National Kidney Foundation when she was diagnosed in 2018 with stage 4 kidney disease. She is currently on home hemodialysis and the transplant waitlist. Ms. DeMeis was the Director of Education and Organizational Development for U R Medicine Home Care. Part of her responsibilities was working with clinicians in teaching them how to present education to patients. She also was the Chairperson of the Patient Family Centered Care program and worked with improving home care through patient advocacy.  In 2018, Ms. DeMeis retired. She had been fighting CKD along with Psoriatic Arthritis for many years and needed to focus on her health.  She currently serves as a member of NKF's Kidney Advocacy Committee, as an Ambassador for NKF's online communities, and also as a NKF Peer mentor. Her other volunteer activities include being on the Board of the Perinton Food Shelf and working with clients as the Lead Verifier.  She and her husband sing with the Perinton Senior Chorus and enjoy working in their garden. Patrick Gee is a Community Activist, fighting against systemic issues such as poverty, social and racial injustices, criminal justice reform, and education reform. Patrick worked for the Virginia Department of Corrections and the Virginia Department of Juvenile Justice, where during his time in service, he acquired several awards and recognitions. In April 2013, Patrick was diagnosed with Stage 3b End-Stage Kidney Disease (ESKD). He began doing Peritoneal Dialysis (PD) in December 2013. On April 21, 2017, Patrick received a kidney transplant. Patrick has been very passionate in his pursuit to speak on behalf of the underserved, undervalued, and disenfranchised communities of color. Because of this, he serves as an advocate and kidney patient expert for a number of organizations including the NKF, CMS, FDA, KHI, AKF, AAKP and HDU.  Patrick was the 2025 winner of NKF's Celeste Lee Castillo Patient Engagement Award.    Additional Resources: GLP-1 Receptor Agonists NKF Supports Proposal to Expand Access to Weight-Loss Medications   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Back pain can affect every aspect of your life. Listen to a rheumatologist discuss common arthritis-related causes of back pain as well as strategies to manage them. *Visit the Live Yes! With Arthritis Podcast episode page to get show notes, additional resources and read the full transcript: https://arthr.org/LiveYes_Ep136 (https://arthr.org/LiveYes_Ep136) * We want to hear from you. Tell us what you think about the Live Yes! With Arthritis Podcast. Get started by emailing podcast@arthritis.org (podcast@arthritis.org). Special Guest: Dr. Vivian Bykerk.

Send us a textIn this powerful episode recorded live at the Winthrop Market, Joey Pinz welcomes Joel Chudnow, a 78-year-old natural hygiene educator with 36 years of experience and a story that's as inspiring as it is practical. Joel opens up about his battle with psoriatic arthritis, the dismissive treatment he received from the traditional medical system, and how that moment became the turning point in his life.Rather than settle for pharmaceuticals, Joel chose the path of education and empowerment. He's since taught at Hillsborough Community College and hosted 923 radio shows featuring holistic health experts from the Tampa Bay area. Joel shares his wellness pillars—meditation, movement, hydration, and gratitude—and how he uses them to maintain health and help others do the same.The episode also touches on trauma recovery, mental wellness, and how acupuncture has supported his healing after Hurricane Milton left him displaced. Joel's motto is clear: focus on gaining health, not losing weight. If you want a dose of hard-earned wisdom, this is your episode. ✅ Top 3 Highlights: